On June 17, 2014, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Co (NYSE:LLY), announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA). Eli Lilly and Co (NYSE:LLY), net profit margin is 17.40% and weekly performance is 5.51%. On last trading day company shares ended up $62.07. Analysts mean target price for the company is $60.88. Eli Lilly and Co (NYSE:LLY), distance from 50-day simple moving average (SMA50) is 4.88%.
HCA Holdings Inc (NYSE:HCA), has received an average recommendation of “Buy” from the seventeen analysts that are covering the stock, Stock Ratings Network reports. Three investment analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $55.50. HCA Holdings Inc (NYSE:HCA), advanced 0.69% in last trading session and ended the day on $58.01. HCA, Gross Margin is 82.60% and its return on assets is 5.40%. HCA Holdings Inc (NYSE:HCA), quarterly performance is 18.90%.
Investment analysts at Stifel Nicolaus boosted their target price on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), to $130.00 in a note issued to investors on Friday. Stifel Nicolaus’ target price would suggest a potential upside of 14.24% from the stock’s previous close. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), shares moved up 0.27% in last trading session and was closed at $124.35, while trading in range of $122.50 – 125.82. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), year to date (YTD) performance is 38.26%.
On June 20, 2014, Akorn, Inc. (NASDAQ:AKRX), announced that it has sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals (NYSE/TSX: VRX) for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its fiscal second quarter earnings call in early August. Akorn, Inc. (NASDAQ:AKRX), ended the last trading day at $29.73. Company weekly volatility is calculated as 3.83% and price to cash ratio as 67.75. Akorn, Inc. (NASDAQ:AKRX), showed a positive weekly performance of 6.83%.
Leave a Reply